ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.132,85
-0,44%
S&P 500
5.836,22
0,16%
Dow Jones
42.297,12
0,86%
Euro vs US Dollar
1,02411
-0,23%
Bitcoin
94.843,68
0,35%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. USOTC

  6. Astellas Pharma Inc (PK) (ALPMY) Börsenkurse

Astellas Pharma Inc (PK)

Astellas Pharma Inc (PK) (ALPMY)

USOTC
9,48
0,01
(0,11%)
Geschlossen 14 Januar 10:00PM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
9,48
Gebot
9,40
Fragen
9,54
Volumen
322.349
9,45 Tagesbereich 9,84
9,15 52-Wochen-Bereich 13,14
Marktkapitalisierung
17,156B
Handelsende
9,47
Handelsbeginn
9,84
Letzte Trade
87
@
9.49
Letzter Handelszeitpunkt
Finanzvolumen
US$ 3.052.208
VWAP
9,4686
Durchschnittliches Volumen (3 Mio.)
241.112
Ausgegebene Aktien
1.809.663.075
Dividendenrendite
5.21%
Kurs-Gewinn-Verhältnis
1,00
Gewinn pro Aktie (EPS)
9,42
Erlöse
1,62T
Nettogewinn
17,05B

Über Astellas Pharma Inc (PK)

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Diversified
Website
www.astellas.com
Hauptsitz
Chuo, Tokyo, Jpn
Gegründet
1984
Astellas Pharma Inc (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker ALPMY. The last closing price for Astellas Pharma (PK) was US$9,47. Over the last year, Astellas Pharma (PK) shares have traded in a share price range of US$ 9,15 to US$ 13,14.

Astellas Pharma (PK) currently has 1.809.663.075 shares in issue. The market capitalisation of Astellas Pharma (PK) is US$17,14 billion. Astellas Pharma (PK) has a price to earnings ratio (PE ratio) of 1.00.

ALPMY Neueste Nachrichten

Weitere Nachrichten

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award PR Newswire NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015 NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015...

04 Juni 2015
PR Newswire (US)

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Mee...

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting PR Newswire TOKYO and NORTHBROOK, Ill., June 1, 2015 TOKYO and...

01 Juni 2015
PR Newswire (US)

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refr...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) - Results from Phase 1/2 trial...

30 Mai 2015
PR Newswire (US)

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Tria...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial Data Presented in Plenary Session at AUA 2015 PR Newswire TOKYO and...

17 Mai 2015
PR Newswire (US)

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting PR Newswire TOKYO and SAN FRANCISCO, May 17, 2015 TOKYO and SAN...

17 Mai 2015
PR Newswire (US)

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be...

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting PR Newswire NORTHBROOK, Ill...

14 Mai 2015
PR Newswire (US)

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting PR Newswire NORTHBROOK, Ill., May 5, 2015 NORTHBROOK, Ill., May 5, 2015 /PRNewswire/...

05 Mai 2015
PR Newswire (US)

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics Exclusive Collaboration Includes Option for Astellas to Acquire Potenza PR Newswire TOKYO and...

22 April 2015
PR Newswire (US)

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function PR Newswire TOKYO, April 6, 2015 TOKYO, April 6, 2015 /PRNewswire/ -- Astellas ("Astellas,") (Tokyo: 4503) today announced...

06 April 2015
PR Newswire (US)

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia PR Newswire TOKYO and HOUSTON, April 3, 2015 TOKYO and HOUSTON, April 3, 2015...

03 April 2015
PR Newswire (US)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.32-3.265306122459.89.929.453115189.60361649DR
4-0.475-4.77147162239.95510.219.38013530049.68690675DR
12-2.52-211212.459.380124111210.20029363DR
26-0.97-9.2822966507210.4513.149.380117791310.71293587DR
52-2.87-23.238866396812.3513.149.1524480110.43851426DR
156-6.59-41.00808960816.0717.969.1517410912.36213795DR
260-7.71-44.851657940717.1918.479.1513546713.17136165DR

ALPMY - Frequently Asked Questions (FAQ)

What is the current Astellas Pharma (PK) share price?
The current share price of Astellas Pharma (PK) is US$ 9,48
How many Astellas Pharma (PK) shares are in issue?
Astellas Pharma (PK) has 1.809.663.075 shares in issue
What is the market cap of Astellas Pharma (PK)?
The market capitalisation of Astellas Pharma (PK) is USD 17,14B
What is the 1 year trading range for Astellas Pharma (PK) share price?
Astellas Pharma (PK) has traded in the range of US$ 9,15 to US$ 13,14 during the past year
What is the PE ratio of Astellas Pharma (PK)?
The price to earnings ratio of Astellas Pharma (PK) is 1
What is the cash to sales ratio of Astellas Pharma (PK)?
The cash to sales ratio of Astellas Pharma (PK) is 0,01
What is the reporting currency for Astellas Pharma (PK)?
Astellas Pharma (PK) reports financial results in JPY
What is the latest annual turnover for Astellas Pharma (PK)?
The latest annual turnover of Astellas Pharma (PK) is JPY 1,62T
What is the latest annual profit for Astellas Pharma (PK)?
The latest annual profit of Astellas Pharma (PK) is JPY 17,05B
What is the registered address of Astellas Pharma (PK)?
The registered address for Astellas Pharma (PK) is 2-5-1 NIHONBASHI-HONCHO, CHUO-KU, CHUO, TOKYO, 103-8411
What is the Astellas Pharma (PK) website address?
The website address for Astellas Pharma (PK) is www.astellas.com
Which industry sector does Astellas Pharma (PK) operate in?
Astellas Pharma (PK) operates in the PHARMACEUTICAL DIVERSIFIED sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
VICPVicapsys Life Sciences Inc (CE)
US$ 1,50
(149.999.900,00%)
207
CRSQCorporate Restaurant Concepts Inc (PK)
US$ 0,99
(82.400,00%)
500
PSRUValiant Eagle Inc (PK)
US$ 0,0002
(19.900,00%)
42,27M
CCTLCoin Citadel (PK)
US$ 0,0002
(19.900,00%)
100k
MOPNMOP Environmental Solutions Inc (CE)
US$ 0,0001
(9.900,00%)
32k
INOQTPT Strategic Inc (CE)
US$ 0,000001
(-100,00%)
500
VGTLVGTel Inc (CE)
US$ 0,000001
(-99,50%)
200k
IFANIFAN Financial Inc (CE)
US$ 0,000001
(-99,50%)
1.000
VAXXVaxxinity Inc (CE)
US$ 0,0004
(-99,20%)
15,6k
GLCOGlobal Links Corporation New (CE)
US$ 0,000001
(-99,00%)
1,5k
PHILPHI Group Inc (PK)
US$ 0,0003
(20,00%)
350,65M
ABQQAB International Group Corporation (PK)
US$ 0,0007
(0,00%)
227,81M
HMBLHUMBL Inc (PK)
US$ 0,0009
(0,00%)
200,68M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0,0037
(-1,33%)
141,32M
RDARRaadr Inc (PK)
US$ 0,0012
(4,35%)
138,46M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

USOTC
ALPMY
Astellas Pharma (PK)
USOTC
BACHY
Bank of China (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten